Austin Wealth Management LLC acquired a new stake in shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 40,250 shares of the company's stock, valued at approximately $393,000. Austin Wealth Management LLC owned 0.17% of Nuvectis Pharma as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Cubist Systematic Strategies LLC bought a new position in Nuvectis Pharma in the fourth quarter worth $34,000. Blue Zone Wealth Advisors LLC bought a new position in Nuvectis Pharma in the first quarter worth $102,000. Baxter Bros Inc. raised its holdings in Nuvectis Pharma by 20.0% in the fourth quarter. Baxter Bros Inc. now owns 15,000 shares of the company's stock worth $81,000 after purchasing an additional 2,500 shares in the last quarter. Squarepoint Ops LLC bought a new position in Nuvectis Pharma in the fourth quarter worth $103,000. Finally, Northern Trust Corp increased its holdings in shares of Nuvectis Pharma by 68.7% during the fourth quarter. Northern Trust Corp now owns 25,725 shares of the company's stock valued at $139,000 after acquiring an additional 10,472 shares in the last quarter. Institutional investors own 96.77% of the company's stock.
Nuvectis Pharma Price Performance
Shares of Nuvectis Pharma stock traded down $0.31 during trading on Friday, hitting $7.88. 44,034 shares of the company's stock traded hands, compared to its average volume of 133,503. The stock has a market capitalization of $164.61 million, a P/E ratio of -6.97 and a beta of -0.25. The business has a 50-day simple moving average of $8.71 and a 200-day simple moving average of $7.99. Nuvectis Pharma, Inc. has a 1 year low of $4.44 and a 1 year high of $11.80.
Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.03. On average, equities analysts predict that Nuvectis Pharma, Inc. will post -1.01 earnings per share for the current fiscal year.
Insider Activity at Nuvectis Pharma
In related news, major shareholder Marlio Charles Mosseri acquired 28,043 shares of the firm's stock in a transaction dated Wednesday, June 18th. The shares were purchased at an average price of $8.05 per share, with a total value of $225,746.15. Following the completion of the purchase, the insider directly owned 2,976,203 shares of the company's stock, valued at $23,958,434.15. This represents a 0.95% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders bought a total of 75,306 shares of company stock valued at $615,781 over the last 90 days. 30.52% of the stock is owned by company insiders.
Analyst Ratings Changes
NVCT has been the subject of several analyst reports. HC Wainwright restated a "buy" rating and set a $15.00 price target (up from $11.00) on shares of Nuvectis Pharma in a report on Wednesday, April 30th. Laidlaw began coverage on Nuvectis Pharma in a report on Monday, March 17th. They set a "buy" rating and a $19.00 price target for the company. Maxim Group began coverage on Nuvectis Pharma in a research report on Wednesday, April 2nd. They set a "buy" rating and a $17.00 price objective on the stock. Finally, Wall Street Zen cut Nuvectis Pharma from a "hold" rating to a "sell" rating in a research report on Sunday, June 29th.
View Our Latest Stock Report on NVCT
About Nuvectis Pharma
(
Free Report)
Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.
Further Reading
Before you consider Nuvectis Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvectis Pharma wasn't on the list.
While Nuvectis Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
